# R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis

> **NCT02842931** · PHASE3 · UNKNOWN · sponsor: **National Research Center for Hematology, Russia** · enrollment: 300 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** R-DA-EPOCH-21
- **DRUG:** R-DA-EPOCH-21 + auto-SCT
- **DRUG:** R-mNHL-BFM-90
- **DRUG:** R-mNHL-BFM-90 + auto-SCT

## Key facts

- **NCT ID:** NCT02842931
- **Lead sponsor:** National Research Center for Hematology, Russia
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2020-02
- **Final completion:** 2023-02
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2016-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02842931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02842931, "R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02842931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*